Cost‐utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide

Documenti analoghi

• Effectiveness and safety of once‐weekly subcutaneous semaglutide versus other glucose‐lowering agents in real‐world patients with type 2 diabetes: A retrospective, observational post‐marketing study
  di: Chenyang Shi, et al.
  Pubblicazione: (2024)
• Weight loss in people with type 1 diabetes over 12 months: Real‐world data comparing tirzepatide, semaglutide and liraglutide
  di: Ebaa Al Ozairi, et al.
  Pubblicazione: (2025)
• Comment on “Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes”
  di: Manish R. Bhise, et al.
  Pubblicazione: (2025)
• Effect of tirzepatide on the risk of diabetic retinopathy in type 2 diabetes
  di: Djordje S. Popovic, et al.
  Pubblicazione: (2024)
• Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic
  di: Jason M. Samuels, et al.
  Pubblicazione: (2025)